Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy

Abstract

OBJECTIVES To review the known histopathologic findings and clinical behavior of mammary analogue secretory carcinoma (MASC). DATA SOURCES PubMed REVIEW METHODS Literature search using the terms “Mammary analogue secretory carcinoma,” “Mammary analog secretory carcinoma,” and “MASC” to identify all relevant publications. RESULTS MASC is an unusual and rare malignant salivary gland tumor first described in 2010. It shares histologic, immunohistochemical, and genetic features with secretory carcinoma of the breast. The clinical behavior of MASC ranges from slowly growing tumors that infrequently recur after surgical resection to aggressive tumors that cause widespread metastasis and death. Many cases of MASC were discovered in archived cases previously classified as acinic cell carcinoma, mucoepidermoid carcinoma, and adenocarcinoma not otherwise specified. CONCLUSION MASC is a newly recognized variant of salivary gland malignancy. Further research is needed to better delineate its overall prevalence and to define an appropriate treatment algorithm for this new clinical entity.

Cytogenetic and immunohistochemical characterization of mammary analogue secretory carcinoma of salivary glands

“…A recent systematic review reports a slight male predominance for MASC (55%) and an average age of 44.2 years (range 14-77) [2]. In our study, the median age for MASC was 51 years (range 12-84) with a lower age in females (33 years) compared to males (71.5 years).…”

“…Mammary analogue secretory carcinoma (MASC) was first described in 2010 as a distinct salivary gland neoplasm, showing close resemblance to secretory carcinoma of the breast (SCB) [1,2]. As well as the histological similarity with SCB, MASC was also shown to harbour the t(12;15) (p13;q25) translocation and the resulting ETV6-NTRK3 fusion gene [1,3,4,].…”

“…The most commonly reported site for MASC is the parotid gland (71%) followed by the submandibular gland (7%) and other sites including soft palate, buccal mucosa, base of tongue and lips [2]. Recently, two cases involving the upper and lower lip have also been reported [28].…”

Salivary Gland Tumor “Wishes” to Add to the Next WHO Tumor Classification: Sclerosing Polycystic Adenosis, Mammary Analogue Secretory Carcinoma, Cribriform Adenocarcinoma of the Tongue and Other Sites, and Mucinous Variant of Myoepithelioma

“…These tumors were termed mammary analogue secretory carcinomas (MASC). Since this initial report, there have been approximately 100 additional cases published [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40]. These have been previously diagnosed as unusual variants of acinic cell carcinoma, adenoid cystic carcinoma, cystadenocarcinoma, mucoepidermoid carcinoma or adenocarcinoma, NOS.…”

Mammary Analogue Secretory Carcinoma of the Parotid Gland: A Rare and Unique Entity

“…Immunocytochemistry of MASC is positive for mammoglobin and S100. Diagnosis of MASC is confirmed with the detection of chromosomal translocation (12;15) (p13;q25) leading to the fusion gene ETV6-NTRK3 [4,[6][7][8]. As a result of this translocation, the tyrosine kinase is constitutively active.…”